Ixaka (formerly Rexgenero) is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease.
Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action.
Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.
Ixaka has offices in London, UK, with R&D and manufacturing operations in Seville, Spain and Paris, France, and additional manufacturing capability in Frankfurt, Germany.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2015
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Ixaka founded?
Ixaka was founded in 2015.
What industry is Ixaka in?
Ixaka operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ixaka based?
Ixaka is headquartered in LONDON, United Kingdom.
Find investors for your startup like Ixaka
Gritt sends AI-personalised outreach to each investor — from your Gmail
